On the AZ/EU dispute thread,
*@wakeupin222* shared a really useful link that give some context. I share here, because they're worth reading.
Two from researchers at Oxford on the initial funding of the vaccine development:
twitter.com/sandyddouglas/status/1355892619944079360
twitter.com/adamjohnritchie/status/1355136430402580482
And this commentary on a UK lawyer on the contract twitter.com/js_oleary/status/1355799338811797504
And this press release on the Oxford Biomedica/Astrazenaca UK manufacturing deal, in which capacity is reserved until end 2021. www.globenewswire.com/news-release/2020/09/01/2086741/0/en/Oxford-Biomedica-Signs-Supply-Agreement-with-AstraZeneca-to-Expand-Manufacturing-Support-of-COVID-19-Vaccine-Candidate-AZD1222.html
It certainly seems on the face of it as vaccines made in the UK are manufactured for AZ UK Ltd at Oxford Biomedica sites, and presumably are owned by them until sold.
Whereas the contract the EU signed was with "AstraZeneca AB, a party incorporated in Sweden".
I am not a lawyer, but on the face of it (as outlined in the commentary on the contract I linked to above) AZAB, with whom the EU signed their contract, does not even own the UK-manufactured doses which the EU is trying to say they should redirect to fulfill their contract. I can't see how even the most stringent definition of "Best Reasonable Efforts" would require anyone to hand over stuff which they have never owned.